Q3 2024 Edwards Lifesciences Corp Earnings Call Transcript
Key Points
- Edwards Lifesciences Corp (EW) reported third-quarter 2024 sales of $1.35 billion, reflecting a 9.6% growth from continuing operations, slightly ahead of expectations.
- The company achieved a strong adjusted gross profit margin of 80.7%, higher than the previous year and sequentially.
- Edwards Lifesciences Corp (EW) is seeing significant growth in its Transcatheter Mitral and Tricuspid Therapies (TMTT) segment, with sales reaching $91 million, a 74% increase over the prior year.
- The company is expanding its product portfolio with new innovations like the PASCAL repair system and the Evoque tricuspid replacement system, which are gaining traction globally.
- Edwards Lifesciences Corp (EW) is actively pursuing new therapeutic areas, such as aortic regurgitation and implantable heart failure management, aligning with its long-term growth vision.
- The company experienced some operational challenges, including the impact of hurricanes in the Southeast and a one-time China distributor rebate adjustment, affecting fourth-quarter sales guidance.
- Edwards Lifesciences Corp (EW) is facing capacity constraints in hospitals, which could impact the growth of its Transcatheter Aortic Valve Replacement (TAVR) procedures.
- The discontinuation of critical care operations and the associated financial adjustments have impacted the company's earnings per share.
- There are concerns about competitive pressures in the market, particularly with new entrants and technologies potentially affecting market share.
- The company anticipates a lower fourth-quarter year-over-year sales growth rate due to one-time items and fewer selling days compared to the third quarter.
Greetings and welcome to Edwards Lifesciences third-quarter 2024 results conference call. (Operator Instructions) Please note that this conference is being recorded.
I will now turn the conference over to your host, Mark Wilterding, Senior Vice President of Investor Relations. Thank you. You may begin.
Thank you very much, Diego, and welcome, everyone. Thank you for joining us this afternoon. With me on today's call is our CEO, Bernard Zovighian and our CFO, Scott Ullem. Also joining us for the Q&A portion of the call will be Larry Wood, our Group President of Teva and surgical structural heart; Daveen Chopra, our global leader of TMTT, and Wayne Markowitz.
Just after the close of regular trading Edwards Lifesciences release third quarter 2024 financial results. During today's call, management will discuss those results included in the press release and accompanying financial statements and then use the remaining time for Q&A.
Please note
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
